Source link : https://www.newshealth.biz/health-news/cilta-cel-improves-os-in-r-r-mm/
RIO DE JANEIRO — A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel, or cilta-cel (CARVYKTI, Janssen Biotech, Inc.), reduces the risk for death by 45% vs standard-of-care (SoC) therapies in patients with lenalidomide-refractory multiple myeloma, according to the latest data from the phase 3 CARTITUDE-4 study. “Cilta-cel is the first […]
Author : News Health
Publish date : 2024-10-03 09:52:37
Copyright for syndicated content belongs to the linked Source.
Categories